Loading
Lineage Cell Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Mar 2026.
Lineage Cell Therapeutics, Inc.: what insiders have been doing
Lineage Cell Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Carlsbad, United States, founded in 1990. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 5 filings were filed, from 2 insiders.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €21k, made by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €21k from Culley Brian M, disclosed on 12 March 2026. Among those who bought: 1 chief executive.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 5 filings here. Over the whole record (from 2016), the tally stands at 18 purchases and 1 sale.
The latest purchase dates back some time: it was published 220 days ago, on 12 March 2026.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Carlsbad, United States · Founded: 1990
Source: Wikidata (CC0).
Insider Decl.
41
Thresholds
n/a
Buy Volume
€13M
18 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySaleBrian M. Culley2 buys
Broadwood Partners, L.P.2 buys
George A. Samuel III1 buy
Jill Ann Howe1 buy
Michael H. Mulroy1 buy
Since the insiders bought
- -20.5%Entry US$1.61 · Close at T+90 US$1.28
- +161.7%Entry US$0.60 · Close at T+365 US$1.57
- -4.7%Entry US$1.50 · Close at T+365 US$1.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Lineage Cell Therapeutics, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$5.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,583 of 24,148 companies
33.1
score / 100
Value15
Quality51
FCF yld-7.3%
Earn yld-24%
EV/EBITDA·
ROE-60%
Gross mgn99%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.06
Analyst consensus
6 analystsStrong buy
US$3.00Target US$5.50(+419%)US$9.00
Income statement
RevenueUS$14.6M
Gross profitUS$14.4M99% margin
EBITDA-US$21.1M-145% margin
Net income-US$63.5M-246.6% margin
Valuation
PER (forward)-10.4x
P/Book4.4x
Beta1.55
Balance sheet & cash
Market capUS$268.1M
Total debtUS$2.4M
Free Cash Flow-US$19.4M
Debt / Equity4%
Profitability & ownership
ROE-60.1%
ROA-17.0%
% insiders4.9%
% institutions51.8%
Last declaration on 12 March 2026
Declarations41 total
15,000 shares@ US$1.6259.0% of flowCommon SharesSEC:0001193125-26-104106:0
Canonical exit: 10 Jun 2026 (T+90)
31,250 sharesCommon SharesSEC:0001193125-26-052021:0
6,075 sharesCommon SharesSEC:0001193125-26-052020:0
1,735 sharesCommon SharesSEC:0001193125-25-327279:0
8,925 sharesCommon SharesSEC:0001193125-25-327280:0
31,249 sharesCommon SharesSEC:0000950170-25-018887:0
6,076 sharesCommon SharesSEC:0000950170-25-018897:0
7,894,737 shares@ US$0.7645.6% of flowCommon SharesSEC:0000919574-25-000555:0
Canonical exit: 27 Apr 2025 (T+90)
00Common SharesSEC:0000919574-25-000555:1
Canonical exit: 27 Apr 2025 (T+90)
15,000 shares@ US$0.60100.0% of flowCommon SharesSEC:0000950170-24-131093:0
Canonical exit: 24 Feb 2025 (T+90)
15,000 shares@ US$0.5949.9% of flowCommon SharesSEC:0000950170-24-131098:0
Canonical exit: 24 Feb 2025 (T+90)
40,000 shares@ US$0.56628.4% of flowCommon SharesSEC:0000950170-24-130592:0
Canonical exit: 20 Feb 2025 (T+90)
40,000 shares@ US$0.609.7% of flowCommon SharesSEC:0000950170-24-129972:0
Canonical exit: 19 Feb 2025 (T+90)
10,500 shares@ US$0.8950.1% of flowCommon SharesSEC:0000950170-24-098731:0
Canonical exit: 14 Nov 2024 (T+90)
10,000 shares@ US$1.054.1% of flowCommon SharesSEC:0000950170-24-064896:0
Canonical exit: 22 Aug 2024 (T+90)
31,249 sharesCommon Shares, no par valueSEC:0001493152-24-005942:0
6,076 sharesCommon Shares, no par valueSEC:0001493152-24-005944:0
96,155 shares@ US$1.04100.0% of flowCommon Shares, no par valueSEC:0001493152-24-005510:0
Canonical exit: 8 May 2024 (T+90)
6,730,770 shares@ US$1.0451.8% of flowCommon SharesSEC:0000919574-24-000757:0
Canonical exit: 6 May 2024 (T+90)
10,000 shares@ US$1.09100.0% of flowCommon Shares, no par valueSEC:0001493152-24-000154:0
Canonical exit: 28 Mar 2024 (T+90)
31,249 sharesCommon Shares, no par valueSEC:0001493152-23-004898:0
13,020 sharesCommon Shares, no par valueSEC:0001493152-23-004895:0
6,076 sharesCommon Shares, no par valueSEC:0001493152-23-004899:0
15,450 sharesCommon Shares, no par valueSEC:0001493152-22-018271:0
15,450 sharesCommon Shares, no par valueSEC:0001493152-22-009000:0
25 of 41 declarations
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company listed in the United States on NYSE American (NYSE/NASDAQ in the broad sense used by many investors), and its corporate headquarters are in Carlsbad, California, United States. The company focuses on developing “off-the-shelf” allogeneic cell therapies designed to address serious medical conditions with substantial unmet need. Its business model is built around a proprietary cell-engineering platform, AlloSCOPE, plus internal development and manufacturing capabilities that matter in cell therapy because consistency, GMP quality, and scalable production can be as important as the biology itself. ([lineagecell.com](https://lineagecell.com/company/))
From a history standpoint, Lineage is the result of a long corporate and strategic evolution that ultimately narrowed the company’s focus toward regenerative medicine and cell therapy. Over time, the business was reshaped into a more specialized biotechnology platform with a clearer clinical pipeline and a sharper identity for capital markets. That repositioning is important for investors because it reduced the company’s “story risk” and made its value proposition more directly tied to a handful of potentially high-value programs. ([investor.lineagecell.com](https://investor.lineagecell.com/node/20211/pdf?utm_source=openai))
Read moreShow less
The pipeline is centered on several programs. The lead asset is OpRegen (RG6501), a retinal pigment epithelial cell therapy being developed with Roche and Genentech for dry age-related macular degeneration, particularly geographic atrophy. In neuroregeneration, OPC1 targets spinal cord injury and remains a key reference point for the company’s scientific reputation. Lineage also develops VAC2 in immuno-oncology, ANP1 for auditory neuron-related hearing loss, and PNC1 for vision loss linked to photoreceptor dysfunction. In practical terms, this makes Lineage a diversified cell-therapy developer, but one still highly concentrated on specialized, high-risk, high-reward indications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/876343/000095017025060148/lctx_2025_ars.pdf))
Competitively, Lineage is positioned as a niche cell-therapy specialist rather than a broad-based biotech. Its potential advantage lies in allogeneic, ready-to-use products that may be easier to manufacture, store, and deploy than patient-specific therapies. Its main challenges are typical of clinical-stage biotech: long development timelines, regulatory uncertainty, financing needs, and competition from larger pharmaceutical groups and better-capitalized peers pursuing alternative approaches in ophthalmology, neurology, and immunology. Geographically, the company is primarily U.S.-based, with headquarters in Carlsbad, California, and additional operational links to Israel through manufacturing and R&D activities described in its filings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/876343/000095017025060148/lctx_2025_ars.pdf))
Recent developments suggest an active clinical and operational year. In 2025, management highlighted 36-month clinical data updates for OpRegen, progress on commercial-scale GMP manufacturing, a new chronic-patient study in OPC1, and a collaboration with William Demant Invest around ReSonance/ANP1 for sensorineural hearing loss. The company’s 2025-2026 SEC Form 4 filings also show ongoing insider transaction activity, which can be useful context for investors following management incentives and insider sentiment. ([investor.lineagecell.com](https://investor.lineagecell.com/node/24211/pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
